Anzeige
Mehr »
Sonntag, 11.05.2025 - Börsentäglich über 12.000 News
Radar vs. Lac Tio: Entsteht hier Nordamerikas nächster Gigant für Titan und Vanadium?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LGJ2 | ISIN: FR0004163111 | Ticker-Symbol: XUP
Tradegate
09.05.25 | 14:10
4,022 Euro
+2,81 % +0,110
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GENFIT SA Chart 1 Jahr
5-Tage-Chart
GENFIT SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,8523,97410.05.
3,8823,94009.05.

Aktuelle News zur GENFIT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiGENFIT S.A.: GENFIT Annual Combined General Meeting of June 17, 2025 - Availability of Preparatory Documents2
MoGenfit S.A. - 6-K, Report of foreign issuer4
MoGENFIT S.A.: GENFIT to Present Latest ACLF Research at EASL Congress 20252
29.04.GENFIT S.A.: GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F1
GENFIT Aktie jetzt für 0€ handeln
29.04.Genfit S.A. - 20-F, Annual and transition report of foreign private issuers-
28.04.GENFIT S.A.: Positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025104Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients...
► Artikel lesen
24.04.Genfit S.A. GAAP EPS of -€0.58, revenue of €38.18M3
24.04.GENFIT S.A.: GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update348Cash and cash equivalents totaled €81.8 million as of December 31, 2024. In addition, completion in early 2025 of: (i) a non-dilutive royalty financing agreement for up to €185 million including a...
► Artikel lesen
24.04.Genfit S.A. - 6-K, Report of foreign issuer2
20.03.GENFIT S.A.: GENFIT Announces Completion of Non-dilutive Royalty Financing Agreement with HCRx and Results of Repurchase Offer to 2025 OCEANEs holders1.002GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million upfront payment with potential for an additional €55 million...
► Artikel lesen
20.03.Genfit S.A. - 6-K, Report of foreign issuer1
10.03.GENFIT S.A.: Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs120All resolutions approved by bondholders Closing of Royalty Financing and receipt of first €130 million instalment expected shortlyUpon closing of the Royalty Financing, GENFIT will implement the Repurchase...
► Artikel lesen
10.03.Genfit S.A. - 6-K, Report of foreign issuer2
27.02.GENFIT S.A.: GENFIT Announces Revenues and Cash Position as of December 31, 2024108Cash and cash equivalents totaled €81.8 million as of December 31, 2024Revenues amounted to €67.0 million as of December 31, 2024 including the €48.7 million milestone upon first sale of Ipsen's Iqirvo®...
► Artikel lesen
21.02.Genfit S.A. - 6-K, Report of foreign issuer-
21.02.Genfit reports preliminary results of repurchase offer to 2025 OCEANEs holders3
21.02.GENFIT S.A.: GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders' general meeting1
14.02.GENFIT S.A.: GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders1
10.02.GENFIT S.A.: GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders5.452In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes: to repurchase...
► Artikel lesen
06.02.GENFIT S.A.: GENFIT Outlines Anticipated New Clinical Trial Initiations, Development Milestones and Data Readouts in 20251602 new ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase...
► Artikel lesen
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1